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Abstract
Glycation, oxidation, and nonenzymatic browning of protein
have all been implicated in the development of diabetic complications. The initial product of glycation of protein, fructoselysine (FL), undergoes further reactions, yielding a complex mixture of browning products, including the fluorescent lysine-arginine cross-link, pentosidine. Alternatively, FL may be
cleaved oxidatively to form Nf-(carboxymethyl)lysine (CML),
while glycated hydroxylysine, an amino-acid unique to collagen, may yield N4-(carboxymethyl)hydroxylysine (CMhL). We
have measured FL, pentosidine, fluorescence (excitation = 328
nm, emission = 378 nm), CML, and CMhL in insoluble skin
collagen from 14 insulin-dependent diabetic patients before and
after a 4-mo period of intensive therapy to improve glycemic
control. Mean home blood glucose fell from 8.7±2.5 (mean±1
SD) to 6.8±1.4 mM (P < 0.005), and mean glycated hemoglobin (HbA,) from 11.6±2.3% to 83±1.1% (P < 0.001). These
changes were accompanied by a significant decrease in glycation of skin collagen, from 13.2±4.3 to 10.6±2.3 mmol FL/mol
lysine (P < 0.002). However, levels of browning and oxidation
products (pentosidine, CML, and CMhL) and fluorescence
were unchanged. These results show that the glycation of longlived proteins can be decreased by improved glycemic control,
but suggest that once cumulative damage to collagen by browning and oxidation reactions has occurred, it may not be readily
reversed. Thus, in diabetic patients, institution and maintenance of good glycemic control at any time could potentially
limit the extent of subsequent long-term damage to proteins by
glycation and oxidation reactions. (J. Clin. Invest. 1991.
87:1910-1915.) Key words: glycation * nonenzymatic browning
* Maillard reaction * diabetes * oxidation

Introduction
The mechanisms underlying the development ofthe complications of diabetes are not fully understood. Even the relationship between glycemic control and the risk of developing complications remains unclear, although there is now a consensus
that hyperglycemia does, in itself, play an important role in the
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development of retinopathy, nephropathy, and neuropathy
(1). The processes of glycation and nonenzymatic browning of
proteins provide an attractive hypothesis to link hyperglycemia
with the development of complications (2-4). The first step in
this reaction pathway, glycation, involves the nonenzymatic
condensation of glucose with free amino groups in the protein,
primarily the e-amino groups of lysine residues, forming the
Amadori adduct, fructoselysine (FL)' (Fig. 1). FL may react
further to initiate a complex series of reactions, which lead to
the accumulation of covalently attached brown and fluorescent
products, cross-links, and other chemical modifications in proteins. These reactions are known collectively as Maillard or
nonenzymatic browning reactions (5, 6). This reaction is
readily illustrated by the browning and cross-linking of proteins on incubation with glucose in physiological buffers in
vitro.
A number of chemical and physical changes occur in human skin collagen with age. Fluorescence, cross-linking, and
resistance to enzymatic degradation increase with age, while
solubility and elasticity decrease (reviewed in 7). In diabetes, in
concert with increased glycation (8-10) and nonenzymatic
browning (1 1-13) of collagen, these age-related changes in the
physical and chemical properties of collagen appear to be accelerated (11-15). This suggests a role for glucose and nonenzymatic browning reactions in the development of age-like chemical and functional alterations ofcollagen in diabetes. Although
the extent of glycation of skin collagen does not appear to correlate directly with the presence of complications in diabetes (9,
10), the long-term effect of increased glycation, i.e., the browning reaction, may be more relevant. Thus, in groups ofinsulindependent diabetic patients, matched for age and duration of
diabetes, there is a significant correlation between skin collagen
fluorescence and the severity of retinopathy, nephropathy, arterial stiffness, and joint stiffness (16). Increased free-radical-mediated oxidative damage to biomolecules, including both lipids
and proteins, has also been proposed as a mechanism contributing to the development of diabetic complications (reviewed in
17, 18). Indeed, free radical reactions may in themselves generate fluorescent products and cross-links in proteins (19), and
thus the changes in collagen with age and in diabetes may be
the combined result of increases in glycation, browning, and
oxidation reactions.
Several distinct chemical products of glycation and browning reactions of protein have now been measured in human
proteins. These compounds (Fig. 1) include the Amadori adduct, FL, and three products of later stages of the Maillard
1. Abbreviations used in this paper: CMhL, N4carboxymethyl)hydroxylysine; CML, N'-(carboxymethyl)lysine; FL, Nf-(l-deoxy-fructose-l-yl)L-lysine; HbA,, hemoglobin A1; MHBG, mean home blood
glucose.
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Figure 1. Maillard reaction pathways for formation of fructoselysine,
pentosidine, and N-(carboxymethyl)lysine. FL is the Amadori compound, the first stable intermediate in the Maillard reaction. CML
and the analogous compound CMhL (not shown), are formed by oxidative cleavage of Amadori adducts to lysine and hydroxylysine, respectively. The mechanism of formation of the fluorescent crosslink,
pentosidine, is unknown.

reaction: pentosidine2 (20-23), N-(carboxymethyl)lysine
(CML) (24-27), and NE-(carboxymethyl)hydroxylysine
(CMhL) (27). The concentration of the initial product, FL, in
long-lived proteins, such as lens proteins (26, 28) and skin collagen (27), increases in response to hyperglycemia in diabetes.
Among the later products of the Maillard reaction, pentosidine
is a fluorescent cross-link formed between lysine and arginine
residues during the browning process (20-23), while CML and
CMhL, which are colorless, are formed by oxidative cleavage of
carbohydrate adducts to lysine and hydroxylysine residues in
protein, respectively (24-27). All three of these late-stage products of the Maillard reaction require oxygen for their formation
(20, 24, 25), i.e., they are either direct products of oxygen radical reactions or are formed by further reaction of oxidation
products. In addition, they all accumulate gradually with age in
skin collagen (27), and at an accelerated rate in diabetes
(21, 23).
In this study, we have measured FL, pentosidine, CML,
and CMhL and Maillard-type fluorescence (excitation (Ex)
= 328 nm, emission (Em) = 378 nm) in insoluble skin collagen
from patients with insulin-dependent diabetes, both before and
after a period of improved glycemic control. Our aim was to
discover ifimprovements in control would lead to a decrease in
the level of any of these Maillard reaction products in diabetic
skin collagen, and thus, perhaps, to a reversal ofthe potentially
damaging effects ofglycation, browning, and oxidation to longlived proteins in diabetes.
2. The compound Maillard Fluorescent Product #1 (MFP-1) described
in references 22 and 23 was originally identified as a fluorescent crosslink formed during browning and cross-linking of proteins by glucose.
MFP-I was isolated and characterized recently in our laboratory and
shown by nuclear magnetic resonance spectroscopy and mass spectrometry to be identical to the compound, pentosidine, previously characterized by Sell and Monnier (20, 21). There is some uncertainty about
whether pentosidine is formed in vivo from ribose (20, 21), glucose (22,
23), or other sugars (23a).

Patient selection. Patients (eight male, six female) with insulin-dependent diabetes mellitus, who were in relatively poor glycemic control,
but motivated to improve, were recruited from the diabetes clinics of
Altnagelvin Hospital, Londonderry, and the Royal Victoria Hospital,
Belfast, Northern Ireland. Their mean age was 31.9±10.5 (19-51) yr
(mean±SD, range), and mean duration of diabetes 12.5±10.6 (0-38)
yr. Three patients had newly diagnosed diabetes. Of the remainder,10
were receiving twice daily injections of regular and NPH (Isophane)
insulin, and one a single daily injection. Mean daily insulin dose was
74±11 (52-88) U. The study was approved by the Ethical and Human
Subjects Committees of the participating institutions, and informed
consent was obtained from all volunteers.
Study design. After an initial assessment, each patient was taught to
perform home blood glucose monitoring using a Memory Glucometer
(Ames Div., Miles Laboratories Inc., Elkhart, IN) and wasgiven a Memory Glucometer on loan for the duration of the study. Patients performed blood glucose measurements four times daily (before meals and
at bedtime) throughout the study. For a 2-wk "run-in" period before
the first skin biopsy, no effort was made to alter glycemic control.
During this period, home blood glucose monitoring results were recorded, and hemoglobin A, (HbA,) was measured on two occasions.
At the end of the run-in period, a full-thickness, elliptical (1.0 0.5
cm) skin biopsy was obtained, under local anesthesia, from the upper
inner aspect of the buttock. The biopsy samples were washed in saline
and stored at -70'C. Patients then entered a program of intensive
management to improve glycemic control, and were seen on an individual basis by one of us (T. Lyons or K. Bailie) at least once every two
weeks. At each visit, the patients received appropriate individual education, including advice on the adjustment of insulin dosage. Between
visits, one of us was available at all times to give advice by telephone.
Each patient was also assessed initially, and subsequently reviewed, as
necessary, by a dietitian. Throughout the study, HbAl measurements
were performed every two weeks. The results of home blood glucose
monitoring were analyzed using the Ames "Glucofacts" program, and
were expressed as "mean home blood glucose" (MHBG) on a weekly
basis. At the conclusion of the study, a second skin biopsy was obtained
from the corresponding site on the opposite buttock. The mean interval between first and second skin biopsies was 120±19 (92-157) d.
Analyticalprocedures. HbAI was measured by agargel electrophoresis (29); the normal range in our laboratory is 3.6-7.2%. Insoluble collagen was isolated from skin biopsy samples by mechanical scraping and
solvent extraction as previously described (9). The preparation of Nformyl-NE-fructoselysine (the standard for the measurement of FL),
CML, and CMhL have been described previously (24, 25,27). A radioactive pentosidine standard was prepared from glucose, N-acetylarginand N"-acetyl-[4,5-3H]ysine of known specific radioactivity, and
purified by reversed phase HPLC (23a). Levels of FL, CML, CMhL,
and lysine in insoluble collagen were measured by gas chromatography/mass spectroscopy with selected ion monitoring (SIM-GC/MS), as
previously described in detail (26, 27). Briefly, for measurement of FL,
(24 h, 1 10C, under
collagen samples were hydrolyzed in 7.8 N
N2), yielding 40% conversion of FL to the analyte, furosine (26, 27, 30).
Because of partial conversion of FL to CML during the hydrolysis
reaction (and possible conversion of glycated hydroxylysine to CMhL),
CML and CMhL were measured separately in NaBH4-reduced samples
(27). Furosine (formed during acid hydrolysis of FL), CML, and CMhL
were measured as their No-trifluoroacetyl methyl ester derivatives by
SIM-GC/MS. The assays were standardized using standard curves prepared by standard addition, and the concentrations were normalized to
the lysine (for FL and CML) or hydroxylysine (for CMhL) content of
the collagen. The pentosidine content of skin collagen was measured,
following NaBH4-reduction and hydrolysis in 6 N (24 h at 1 10°C),
by reversed phase HPLC using fluorometric detection (Ex = 328nm,
Em = 378nm) (22, 23a). Quantitation was based on fluorescence area
units, using a standard curve prepared with known amounts of authen-
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measurement of fluorescence (Ex = 328nm, Em = 378nm), collagen
was digested with pepsin (5%, wt/wt) in 0.5 M acetic acid (adjusted to
pH 2 with 6 M HC1), for 24 h at 37°C. The samples were clarified by
centrifugation for measurement of fluorescence. More than 98% ofthe
hydroxyproline content of the skin sample, determined as previously
described (9), was solubilized by this method. The fluorescence readings were normalized to the hydroxyproline content of the solution.
For each analysis all samples were analyzed together in a single batch to
avoid interassay variations. All laboratory work on the samples was
also done "blind", i.e., with no knowledge of sample identity.
Statistics. Results are expressed throughout as mean± I SD. Differences between groups before and after improved glycemic control were
compared using a paired t test.

Table I. Glycation and Oxidation Products in Insoluble Skin
Collagen before and after Improved Glycemic Control
Measurement*

MHBG (mM)

HbAj(%)
mmol FL/mol Lys
mmol CML/mol Lys

mmol CMhL/mol Hyl

Results

gmol pentosidine/mol Lys

Measurements of both MHBG and HbA, (Fig. 2) show that
there were significant improvements in glycemic control in the
patient group during the course of this study. The overall differences and statistical analyses for these and other measurements
discussed below are summarized in Table I. Fig. 3 shows the
results of all the analyses for individual patients. It is apparent
that, in addition to MHBG (Figs. 2 A and 3 A) and HbAl (Figs.
2 B and 3 B), the extent of glycation of skin collagen also decreased significantly between the beginning and end of the
study (Fig. 3 C and Table I). Glycation of collagen correlated
significantly with MHBG (r = 0.65, P < 0.02) and HbA, (r
= 0.89, P < 0.0001) at the beginning, but not at the end, of the
study. Similarly, MHBG during the 2-wk run-in period correlated significantly with initial HbA, (r = 0.56, P < 0.05), but, as
might be expected, this correlation was lost with improved glycemic control. Over the course of the study, the relative decrease in individual patient HbAl ([initial-final]/initial) corre-
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8.7±2.5

6.8±1.4
(4.0-9.2)
8.3±1.1
(6.8-10.2)
10.6±2.3
(7.1-15.2)
0.78±0.45
(0.14-1.86)
2.19±1.11
(0.49-4.48)
9.7±6.4
(1.0-23.7)
1.22±0.51
(0.40-2.33)

<0.005

(4.0-12.8)
11.6±2.3
(76-16.6)
13.2±4.3
(7.2-22.7)
0.78±0.46
(0.20-1.81)
2.18±1.06
(0.73-4.40)
9.6±6.6
(1.5-22.5)
1.25±0.62
(0.34-2.55)

<0.001

<0.002
NS
NS

NS
NS

* Mean±SD; ranges shown in parentheses.
$ Significance estimated by paired t test; NS, P > 0.1.

lated significantly with the relative decreases in MHBG (r
= 0.68, P < 0.01) and FL in collagen (r = 0.72, P < 0.005).
Thus, changes in mean blood glucose concentration were
mirrored by changes in glycation of both hemoglobin and collagen. This is apparent in Fig. 3, A-C, which shows visually that
the greatest reductions in collagen FL occurred in those patients with highest initial FL values and who achieved the greatest decreases in MHBG and HbA,.
As shown in Fig. 3, D-G and summarized in Table I, levels
of CML, CMhL, pentosidine, and total fluorescence were unaffected by the 4-mo period of improved glycemic control. All of
these parameters showed wide variations among individuals,
reflecting differences in age (Fig. 3), as well as duration and
severity of diabetes. There were no significant correlations of
MHBG, HbA,, or collagen FL with CML, CMhL, pentosidine,
or total fluorescence.
One other important observation made in this study is summarized in Fig. 4 and its legend. In diabetic patients, either at
the beginning or end of the study, there was a strong correlation
between any two of the measures of long-term chemical modification ofcollagen, i.e., nonenzymatic browning products (pentosidine), oxidation products (CML and CMhL), and total fluorescence. Thus, the four parameters measured in this study
provide a consistent assessment of the extent of Maillard reaction damage to collagen.

Discussion
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Figure 2. Sequential mean home blood glucose (A) and HbA, (B)
results (mean±I SD) for all 14 patients during the course of the study.
The first skin biopsies were performed at time 0.
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Collagen, in its various forms, is a ubiquitous protein in the
body. Collagen abnormalities may therefore have widespread
consequences, such as interference with basement membrane
function in small vessels and glomeruli, or with the processes of
growth and remodelling oftissues. Such problems are well recognized features of long-term diabetes. Increased glycation and
nonenzymatic browning of collagen and other structural proteins by glucose is thought to be one of perhaps several mechanisms contributing to pathophysiological changes characteris-
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difficult to estimate an exact half-time for reversal of glycation
of human skin collagen. However, the results of this study suggest that the half-time for response of collagen glycation to
improvements in glycemic control may be as short as 4 mo.
This conclusion is drawn from analysis of individual percent
decreases in HbAl and collagen FL, normalized to the percent
decrease required to achieve the means ofthe nondiabetic population (5.5% HbAI, and 4.6 mmol FL/mol Lys in skin collagen) (27). For example, the response in collagen glycation was
calculated as 100 x (FLi - FLf)/FLi - FLm), where FLi, FLf
refer to the initial and final measurements of mmol FL/mol
Lys in collagen, and FLm = 4.6 mmol FL/mol Lys in collagen,
the mean value for the nondiabetic population (27). By this
analysis there was an average 45% decrease in HbA, and 25%
decrease in glycation of collagen (r = 0.68, P < 0.01) toward the
nondiabetic means. The greater response in HbA, is consistent
with the increased rate of turnover of hemoglobin, compared
to skin collagen. The 25% decrease in glycation of collagen
within a 4-mo period indicates that the upper limit for the
half-time for reversal of collagen glycation is 8 mo. The
actual half-time is undoubtedly shorter since none of the patients achieved normoglycemia instantaneously or maintained
normoglycemia throughout the course ofthe study. For the six
patients in poorest control at the beginning ofthe study (initial
HbAI > 12.0%, marked by an asterisk in Fig. 3 B), the average
decreases toward the nondiabetic means during the course of
the study were 66% for MHBG, 64% for HbA,, and 36% for
glycation of collagen (see Fig. 3, A-C). These results suggest
that if glycemia were completely and instantaneously normalized at the beginning of the study (i.e., 100% decrease to normal
in MHBG), it should have been possible to achieve a 50% decrease towards normal in glycation of collagen within the 4-mo
period of our study, suggesting an actual half-time closer to 4
mo for reversal of the excessive glycation of collagen. A more
rigorous mathematical analysis cannot be justified because of
the lack of information about the kinetics of collagen glycation
and the mechanisms by which collagen FL content was decreased.
There are a number of possible explanations for the decrease in glycation of collagen during improved glycemic control. All assume a decrease in the rate of glycation in response
to the fall in ambient glucose concentration, plus some reaction in which the existing glucose adducts are consumed. Assuming negligible turnover of insoluble skin collagen (35-38),
one possible explanation for the decrease in glycation is that the
reaction of glucose with lysine may be reversible, the hexose
being released as glucose and mannose stereoisomers, regener-
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Figure 3. Individual
changes in indices of
glycemic control (A, B),
and glycation (C), nonenzymatic browning (D,
E), and oxidation (F,
G) of collagen during
the course of the study.
Two data points are
missing from the pentosidine (D) and total fluorescence (E) results,
because of insufficient
sample. Asterisks in B
denote patients with
initial HbAj > 12%.

tic of aging (31) and the development of the complications of
diabetes (3, 5, 6, 16). The extent of glycation of long-lived proteins is directly related to ambient glucose concentration (2628) and does not change significantly with age in the nondiabetic population (26-28, 32, 33). While a number of earlier
studies have shown that glycation of collagen -is increased in
response to hyperglycemia in diabetes (8-10, 15) and have
found a strong correlation between glycation of hemoglobin
and collagen (9, 10), our work demonstrates that glycation of
human skin collagen may be significantly reduced within as
short a time as a 4-mo period of improved glycemic control. To
our knowledge only one other study (34) has addressed the
question of reversibility of glycation of collagen. In that case
the investigators found no decrease in glycation of tail tendon
collagen in diabetic rats treated with insulin for an 8-wk period.
The failure to detect differences in collagen glycation in these
animal experiments may be explained by the shorter period
studied.
Because of the impracticality of maintaining constant glycemia and obtaining multiple skin biopsies from patients, it is
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Figure 4. Correlations
between pentosidine
and total fluorescence
or CML in skin collagen. These data are
from analyses of the initial biopsy samples. All
six of the possible paired

correlations between
pentosidine, fluores-

cence, CML, and CMhL
had r 2 0.9 and P <
0.001 in both initial and
final collagen samples.
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ating the unmodified lysine residue. As reviewed in reference
39, there is firm evidence for reversal of the Amadori rearrangement with model Amadori compounds (24), but little information on the rate or extent of reversal of glycation ofproteins in
vivo. It is also possible that the Amadori adduct is consumed in
a forward reaction, resulting, for example, in the release of the
carbohydrate in a modified form, such as 1- or 3-deoxyglucosone (40), again regenerating the unmodified lysine residue in
collagen. The precision of our analyses do not permit us to
determine whether the loss of FL in collagen is accompanied by
an increase in the lysine content of the protein. Thus, it is also
possible that the FL may be consumed in fragmentation and
oxidation reactions, leading to formation ofbrowning and oxidation products, including pentosidine, CML (CMhL), and
other species. However, the further progress of these reactions
should be limited by the decrease in the precursor, FL.
In contrast to FL, levels of CML, CMhL, pentosidine, and
total fluorescence in collagen did not respond to improved glycemic control within the period ofthis study. This is consistent
with the fact that, to our knowledge, these compounds are
stable and irreversible chemical modifications of protein; they
are known to accumulate with age in long-lived proteins, such
as lens crystallins (26) and the insoluble fraction of skin collagen (21, 27). Their constant concentration in collagen during
the limited course of this study is also consistent with the metabolic inertness ofinsoluble human skin collagen (35-38), while
the strong correlations between the concentrations of these
compounds in collagen (Fig. 4) emphasize that they are all
sensing the same chemical environment and stresses. While
our results show that glycation of collagen may be reduced by
improved glycemic control, they also indicate that browning
and oxidation products formed during advanced stages of the
Maillard reaction result in relatively permanent, perhaps irreversible, modification of the protein. These considerations add
further weight to the argument that the establishment and
maintenance ofgood glycemic control may inhibit the development of diabetic complications.
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